BURU vs IPGP vs LYRA

For growth investors, IPG Photonics Corporation (IPGP) is the stronger pick with 2.

7% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). IPG Photonics Corporation (IPGP) offers the better valuation at 139. 2x trailing P/E (62. 6x forward), making it the more compelling value choice. Analysts rate IPG Photonics Corporation (IPGP) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IPG Photonics Corporation (IPGP) delivered a total return of -48.

5%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: IPGP returned +20. 2% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.

(LYRA) is the lower-risk stock at 0. 65β versus IPG Photonics Corporation's 1. 80β — meaning IPGP is approximately 179% more volatile than LYRA relative to the S&P 500.

By revenue growth (latest reported year), IPG Photonics Corporation (IPGP) is pulling ahead at 2.

7% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: IPG Photonics Corporation grew EPS 117. 8% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IPG Photonics Corporation (IPGP) is the more profitable company, earning 3.

1% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps 3. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IPGP leads at 1. 3% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lyra Therapeutics, Inc.

(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). IPG Photonics Corporation (IPGP) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYRA: -100. 0%, IPGP: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BURU (Industrials) and IPGP (Technology) and LYRA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.